$BCRX FDA approves BioCryst's intravenous flu drug Dec 22 (Reuters) - The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals Inc's intravenous flu drug, sending the company's shares up nearly 10 percent in premarket trading.
The single-dose drug is for adults who have acute uncomplicated influenza and may be unable to swallow pills, such as Gilead Sciences Inc's Tamiflu, or inhale GlaxoSmithKline Plc's Relenza.
"An IV (intravenous) drug would ensure that an appropriate dose is administered, which is a concern for oral and inhaled drugs in severely ill patients," Needham & Co analyst Serge Belanger said.
Biocryst's peramivir injection, to be sold as Rapivab, is the first antiviral influenza treatment approved by the FDA in fifteen years, the company said on Monday.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.